# References

Marafini I, Sedda S, Dinallo V, Monteleone G (2019) Inflammatory cytokines: from discoveries to therapies in IBD. Expert Opin Biol Ther 19(11):1207–1217

Matsumoto S, Nagaoka M, Hara T, Kimura-Takagi I, Mistuyama K, Ueyama S (2004) Fucoidan derived from Cladosiphon okamura-nus Tokida ameliorates murine chronic colitis through the down-regulation of interleukin-6 production on colonic epithelial cells. Clin Exp Immunol 136(3):432–439

Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theu-rich S, Hausen AC, Schmitz J, Brönneke HS (2014) Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 15(5):423–430

McAlindon M, Hawkey C, Mahida Y (1998) Expression of inter-leukin 1β and interleukin 1β converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 42(2):214–219

McGee D, Bamberg T, Vitkus S, McGhee J (1995) A synergistic relationship between TNF-alpha, IL-1 beta, and TGF-beta 1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line. Immunology 86(1):6

Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M (2012) IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci 122(4):143–159

Mitsuyama K, Tomiyasu N, Suzuki A, Takaki K, Takedatsu H, Masuda J, Yamasaki H, Matsumoto S, Tsuruta O, Toyonaga A (2006) A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol 143(1):125–131

Mitsuyama K, Toyonaga A, Sasaki E, Ishida O, Ikeda H, Tsuruta O, Harada K, Tateishi H, Nishiyama T, Tanikawa K (1995) Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 36(1):45–49

Modur V, Li Y, Zimmerman GA, Prescott SM, McIntyre TM (1997) Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Investig 100(11):2752–2756

Molodecky NA, Kaplan GG (2010) Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 6(5):339

Monteleone G, Fina D, Caruso R, Pallone F (2006) New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol 22(4):361–364

Mudter J, Neurath MF (2007) Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 13(8):1016–1023

Mülberg J, Schooltink H, Stoyan T, Günther M, Graeve L, Buse G, Mackiewicz A, Heinrich PC, Rose-John S (1993) The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 23(2):473–480

Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T (1988) The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 167(2):332–344

Murch S, Braegger C, Walker-Smith J, MacDonald T (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34(12):1705–1709

Naito Y, Takagi T, Uchiyama K, Kuroda M, Kokura S, Ichikawa H, Yanagisawa R, Inoue K-I, Takano H, Satoh M (2004) Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice. Int J Mol Med 14(2):191–196

Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S (2021) Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 56(6):489–526

Neuman MG, Nanau RM (2012) Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res 160(1):29–44

O’Reilly S, Ciechomska M, Cant R, van Laar JM (2014) Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem 289(14):9952–9960

O’Reilly S (2021) Circulating Gremlin-1 is elevated in systemic sclerosis patients. J Scleroderma Relat Disorders 6(3):286–289

Oakley RH, Cidlowski JA (2013) The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol 132(5):1033–1044

Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, Nishihara M, Iwakura Y, Hirano T (2008) Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29(4):628–636

Okamoto R, Tsuchiya K, Nemoto Y, Akiyama J, Nakamura T, Kanai T, Watanabe M (2009) Requirement of Notch activation during regeneration of the intestinal epithelia. Am J Physiol-Gastrointest Liver Physiol 296(1):G23–G35

Ota M, Yanagisawa M, Tachibana H, Yokota K, Araki Y, Sato K, Mimura T (2015) A significant induction of neutrophilic chemoattractants but not RANKL in synoviocytes stimulated with interleukin 17. J Bone Miner Metab 33(1):40–47

Pandurangan AK, Mohebali N, Hasanpourghadi M, Looi CY, Mustafa MR, Mohd Esa N (2016) Boldine suppresses dextran sulfate sodium-induced mouse experimental colitis: NF-κB and IL-6/STAT3 as potential targets. BioFactors 42(3):247–258

Park H-J, Kim D-H, Lim S-H, Kim W-J, Youn J, Choi Y-S, Choi J-M (2014) Insights into the role of follicular helper T cells in autoimmunity. Immune Network 14(1):21–29

Pawłowska-Kamieniak A, Krawiec P, Pac-Kożuchowska E (2021) Interleukin 6: biological significance and role in inflammatory bowel diseases. Adv Clini Exp Med 30(4):465–469

Pincus T, Sokka T (2009) Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin 35(4):731–734

Pizarro TT, Michie MH, Bentz M, Woraratanadharm J, Smith MF, Foley E, Moskaluk CA, Bickston SJ, Cominelli F (1999) IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells. J Immunol 162(11):6829–6835

Powell N, Lo JW, Biancheri P, Vossenkämper A, Pantazi E, Walker AW, Stolarczyk E, Ammoscato F, Goldberg R, Scott P (2015) Interleukin 6 increases production of cytokines by colonic innate lymphoid cells in mice and patients with chronic intestinal inflammation. Gastroenterology 149(2):456–467

Qu S, Fan L, Qi Y, Xu C, Hu Y, Chen S, Liu W, Liu W, Si J (2021) Akkermansia muciniphila Alleviates dextran sulfate sodium (DSS)-induced acute colitis by NLRP3 activation. Microbiol Spect 9(2):e00730-e1721

Rather IA, Bajpai VK, Ching LL, Majumder R, Nam G-J, Indugu N, Singh P, Kumar S, Hajrah NH, Sabir JS (2020) Effect of a bioactive product SEL001 from Lactobacillus sakei probio65 on gut microbiota and its anti-colitis effects in a TNBS-induced colitis mouse model. Saudi J Biol Sci 27(1):261–270

Reinisch W, Gasché C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, Dejaco C, Waldhör T, Bakos S, Vogelsang H (1999) Clinical relevance of serum interleukin-6 in Crohn’s disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 94(8):2156–2164

Reiter A, Bengesser SA, Hauschild A-C, Birkl-Töglhofer A-M, Fellen-dorf FT, Platzer M, Färber T, Seidl M, Mendel L-M, Unter-weger R (2020) Interleukin-6 gene expression changes after a 4-week intake of a multispecies probiotic in major depressive